The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

When I was big, I would ask her to make those things. But when I stopped asking for them after starting Zepbound, the kids stopped asking too. So we’re all doing a lot less late-night snacking.

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... with shares of Hims & Hers Health, a company offering compounded versions of GLP-1 treatments ...

Zepbound, which has the same active ingredient ... Keerthi Reddy, 32, who underwent bariatric surgery a few years back, took her first Mounjaro shot this week at Vennapusa's clinic.

Zepbound, which has the same active ingredient ... Keerthi Reddy, 32, who underwent bariatric surgery a few years back, took her first Mounjaro shot this week at Vennapusa's clinic. "My friends and ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

Millions of Americans are on their way to healthier weights. We’re following the big shifts in their lives. A 46-year-old dad tells how his life has changed. (Photo illustration: Yahoo News ...

Patients regularly taking Eli Lilly & Co.’s obesity shot Zepbound tend to keep the weight off for at least three years, with most regaining 5% or less of the pounds they shed. A company-funded ...

That was music to the ears of investors in Novo Nordisk, which makes diabetes and obesity treatments Ozempic and Wegovy; and in Eli Lilly, which makes Mounjaro and Zepbound diabetes and obesity drugs.